Log In
Print
BCIQ
Print
Print this Print this
 

elotuzumab (BMS-901608, HuLuc63) (formerly PDL 063)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionHumanized mAb targeting SLAM family member 7 (SLAMF7; CS1)
Molecular Target SLAM family member 7 (SLAMF7) (CS1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed or refractory multiple myeloma (MM)
Regulatory Designation U.S. - Breakthrough Therapy (Treat relapsed or refractory multiple myeloma (MM));
Switzerland - Orphan Drug (Treat multiple myeloma (MM))
Partner Bristol-Myers Squibb Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today